SCHEMBL27041435

SCHEMBL27041435

C[C@H]1CCCN(Cc2cc3c(C4CC4)cn(-c4cccc(C5(c6nnco6)CC(F)(F)C5)c4)c(=O)c3[nH]2)C1

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 14/20 0.36
▸ HSD17B10 Q99714 1/20 0.30
▸ CBL P22681 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27068272 0.93 — —
SCHEMBL27068278 0.90 CBLB (0.35) CBLBHSD17B10
SCHEMBL27068276 0.89 CBLB (0.39) CBLBHSD17B10CBL
SCHEMBL30728175 0.89 CBLB (0.39) CBLBHSD17B10CBL
SCHEMBL30728232 0.87 CBLB (0.48) CBLBCBL
SCHEMBL27068279 0.85 CBLB (0.38) CBLBCBL
SCHEMBL32666905 0.82 CBLB (0.37) CBLBHSD17B10
SCHEMBL30999266 0.82 CBLB (0.51) CBLB
SCHEMBL32666859 0.82 CBLB (0.35) CBLB
SCHEMBL30728164 0.81 CBLB (0.47) CBLBCBL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-01-29 — — US disclosed
EP-4558501-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-05-28 — — EP disclosed
WO-2024020034-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBL, CBLC CBLB 1/4885HSD17B10 1224/4885CBL 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback